MILTEFOSE is an oral antiprotozoal medication active against different forms of leishmaniasis. Miltefosine is the first oral agent approved for visceral leishmaniasis, offering a non-injectable alternative to traditional therapies.
Mechanism of action:
Miltefosine disrupts parasite cell membrane integrity, interferes with phospholipid metabolism, and induces apoptosis in Leishmania cells, leading to parasite elimination.
Recommended for:
Clinical trials conducted in endemic regions such as India, Brazil, and Africa have demonstrated cure rates exceeding 90% when used according to recommended treatment protocols. Miltefosine is included in WHO guidelines for leishmaniasis management.
Indicated for the treatment of visceral, cutaneous, and mucocutaneous leishmaniasis. Works by disrupting parasite cell membranes and inhibiting replication.
Take orally after meals with water. Dosage and duration depend on body weight and disease type and must be prescribed by a healthcare professional. Adherence to the full treatment course is essential.
Contraindications
Side Effects
